On August 26, 2019, the newly revised Drug Administration Law (“New Law”) was officially issued. The promulgation of the New Law has established a new legal regulatory framework, resulted in significant changes for the pharmaceutical and healthcare industry, and promoted international integration. Given its implications for current and future market participants, timely interpretation of the law is required by local and foreign companies operating in the Chinese healthcare sector.
KWM Insights: Special Issue for the New Drug Administration Law was co-published by King & Wood Mallesons and KWM Institute. Nearly 20 partners who specialize in pharmaceutical and healthcare law, provided their insights covering a broad range of topics relating to the New Law, including drug marketing authorization holder system, online sales of prescription drugs, clinical trials, regulations on imported drugs, and liability for fake and inferior medicines.